Aligos Therapeutics (NASDAQ:ALGS) Releases Earnings Results, Misses Expectations By $0.78 EPS

Aligos Therapeutics (NASDAQ:ALGS) posted its earnings results on Monday. The company reported ($3.41) EPS for the quarter, missing analysts’ consensus estimates of ($2.63) by ($0.78), Zacks reports. Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%.

Aligos Therapeutics Price Performance

NASDAQ ALGS opened at $11.60 on Monday. Aligos Therapeutics has a 1 year low of $6.76 and a 1 year high of $46.80. The company has a fifty day moving average of $27.25 and a two-hundred day moving average of $20.58. The company has a market capitalization of $41.60 million, a PE ratio of -0.89 and a beta of 2.52.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).